Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Study tests if potent weed vapes lead to overconsumption

NCT ID NCT07105449

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether regular cannabis users can adjust how much they vape when using high-potency concentrates (30%, 60%, and 90% THC). Researchers will measure blood THC levels, puffing behavior, and subjective feelings of intoxication. The goal is to understand if people naturally limit their intake with stronger products, which could inform safety regulations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cannabis (THC concentrates at 30%, 60%, and 90% potency)
What this could lead to
If successful, this study could provide evidence to guide regulations on high-potency cannabis products, potentially reducing public health risks like addiction and psychosis.
What could go wrong
This is a small, early-phase study with only 48 participants, so results may not apply to all users. It focuses on acute effects, not long-term harms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 19-55 years. * Frequency of primary exposure to cannabis 1-4 occasions per week, through any route of administration, over the past three months; participants must report experience with vaping high-potency liquid concentrates with more than 3 exposures to 90% THC and willingness to use such products in the study. * Refrain from cannabis for 48 hours and from alcohol for 12 hours before visits. * Agree not to drive a car for 24 hours after each visit. * Abstain from recreational drugs for at least 48 hours prior to each visit. * Abstain from any drugs not medically required. * Well-controlled blood pressure for participants with hypertension. Exclusion Criteria: * Pregnant/breastfeeding (women of childbearing potential must have a negative pregnancy test and report use of appropriate contraception). * Evidence of cardiac arrhythmias/failure, ischaemic heart disease. * Recent open heart/open chest surgery or cataract surgery. * Evidence from Structured Clinical Interview for DSM-5 \[SCID-5-CT\] or clinical evaluation of lifetime psychotic disorder/schizophrenia or bipolar disorder; family history of a first-degree relative with a diagnosis of psychotic disorder or schizophrenia; history of psychiatric co-morbidities in the past year (major depression, anxiety disorder or suicide attempt in past year or current suicidal ideation) and current substance use disorder/dependence. * Evidence of neurological illness (e.g., stroke, epilepsy, traumatic brain injury). * Renal or hepatic abnormalities (self-report and blood hematology/chemistry); and * Respiratory diseases, including asthma and physician-diagnosed lung disease. * Taking prescribed medications that contain either THC or cannabidiol (CBD). * Participation in another clinical or non-therapeutic study in the last three months. * Bleeding disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre for Addiction and Mental Health

    RECRUITING

    Toronto, Ontario, M5T 1R8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.